GO
Loading...

Drug Retail

More

  • The $84,000 drug debate  Friday, 25 Jul 2014 | 2:50 PM ET

    CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.

  • Drug costs hit insurers: Gilead still a buy?  Friday, 25 Jul 2014 | 12:15 PM ET

    CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.

  • FedEx indicted for prescription roulette  Friday, 18 Jul 2014 | 1:53 PM ET

    CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.

  • Next global epidemic?  Tuesday, 15 Jul 2014 | 1:40 PM ET

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Financing legal pot  Tuesday, 8 Jul 2014 | 4:50 PM ET

    David Dinenberg, Kind Banking founder and CEO, provides insight to his business model of providing financing to the new legal pot industry.

  • Wild ride for MannKind's Afrezza  Monday, 30 Jun 2014 | 1:12 PM ET

    The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.

  • Pot start-ups pitch to angel investors  Monday, 23 Jun 2014 | 2:41 PM ET

    Paid members of the Arcview Group have committed to investing at least $50,000 into the budding cannabis industry. Members are in Denver hearing pitches from pot start-ups, reports CNBC's Josh Lipton.

  • Incyte CEO: Science will drive success  Monday, 2 Jun 2014 | 2:52 PM ET

    Incyte CEO Herve Hoppenot, provides insight to his company's progress on cancer research at this year's ASCO conference.

  • Ariad CEO talks Iclusig trials  Monday, 2 Jun 2014 | 12:34 PM ET

    Ariad Pharmaceuticals CEO Dr. Harvey Berger, says investors are responding to his company's better overall picture, and the progress on its leukemia drug Iclusig.

  • ASCO cancer care conference kicks off  Friday, 30 May 2014 | 1:01 PM ET

    In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.

  • Costco results miss estimates as costs rise Thursday, 29 May 2014 | 5:24 AM ET
    A Costco store in Alhambra, Calif.

    Costco reported third-quarter results below analysts' estimates hurt by an increase in merchandise costs and other expenses.

  • Over-the-counter Cialis?  Wednesday, 28 May 2014 | 2:16 PM ET

    CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.

  • Zeroing in on rising drug prices  Friday, 23 May 2014 | 4:32 PM ET

    CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.

  • Big move for PTC Therapeutics  Friday, 23 May 2014 | 2:40 PM ET

    PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.

  • Drug pricing in US versus world  Friday, 23 May 2014 | 1:49 PM ET

    CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.

  • Ethics of 'right to try' laws  Tuesday, 6 May 2014 | 2:35 PM ET

    Lawmakers in four states are considering changing the rules to allow terminally ill people access to experimental drugs before they have FDA approval. Kenneth Goodman, University of Miami, thinks this would be a bad bet for patients. Miles Nadal, MDC Partners Chairman & CEO, weighs in.

  • Pharma deal of the day  Tuesday, 6 May 2014 | 12:27 PM ET

    CNBC's Meg Tirrell spoke with Merck Chairman & CEO Ken Frazier about the company's decision to sell its over the counter health care products to Bayer.

  • Activist Jana sees opportunities in this stock Tuesday, 22 Apr 2014 | 4:07 PM ET
    Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.

  • Eli Lilly acquires Novartis' animal health unit  Tuesday, 22 Apr 2014 | 7:18 AM ET

    Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.

  • GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.